SCHEMBL5147786

SCHEMBL5147786

FC(F)Oc1ccc(C2CCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
TSHR P16473 1/20 0.44
MDM2 Q00987 1/20 0.44
IDO1 P14902 1/20 0.42
KCNH2 Q12809 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
HAO1 Q9UJM8 1/20 0.41
KMT2A Q03164 4/20 0.41
LMNA P02545 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SLC6A4 P31645 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
DRD1 P21728 1/20 0.39
MEN1 O00255 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5144846 0.98 KCNH2 (0.44) ALDH1A1TSHRMDM2IDO1KCNH2
SCHEMBL5144864 0.96 DRD1 (0.43) ALDH1A1TSHRMDM2IDO1KCNH2
SCHEMBL5146469 0.92 IDO1 (0.47) ALDH1A1TSHRMDM2IDO1KMT2A
SCHEMBL8766989 0.89 IDO1 (0.42) ALDH1A1TSHRMDM2IDO1KMT2A
SCHEMBL4063657 0.85 IDO1 (0.41) ALDH1A1TSHRMDM2IDO1KMT2A
SCHEMBL8452616 0.85 NPC1 (0.46) ALDH1A1IDO1KMT2ANPC1RAB9A
SCHEMBL14924284 0.83 ESR2 (0.52) ALDH1A1TSHRMDM2IDO1HRH3
SCHEMBL8767282 0.81 MAPT (0.43) ALDH1A1TSHRMDM2IDO1SLC6A4
SCHEMBL13906280 0.80 IDO1 (0.41) ALDH1A1TSHRMDM2IDO1KMT2A
SCHEMBL13906289 0.80 IDO1 (0.41) ALDH1A1TSHRMDM2IDO1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009032249-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK & CO., INC. (US) 2009-03-12 WO disclosed
US-20070299072-A1 KV1.5 POTASSIUM CHANNEL INHIBITORS WYETH (US) 2007-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299072-A1 KV1.5 POTASSIUM CHANNEL INHIBITORS KCNA5, KCNH1, KCNK5 ALDH1A1 888/4885TSHR 1447/4885MDM2 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.